DEFA14A: Nutex Health Amends Proxy Statement, Details Equity Plan Dilution and Merger-Related Stock Compensation

Nutex Health Inc. has issued a supplement to its proxy statement, providing additional disclosures on the potential dilutive impact of its proposed equity incentive plan amendment and detailing significant stock-based compensation related to prior hospital mergers.

Summary

• The supplement updates the proxy statement for the Annual Meeting on July 14, 2025, primarily to provide additional tabular disclosure on the anticipated dilutive effect of the 2023 Equity Incentive Plan amendment and related historical burn rate.
• Stockholders will vote on re-electing six current directors and electing Frank E. Jaumot as a new director.
• An advisory vote on executive compensation is scheduled.
• A key proposal is to amend the 2023 Equity Incentive Plan to increase shares available for issuance by 1,100,000 and to allow for an automatic annual increase of up to 5% of outstanding shares, subject to Board discretion.
• Stockholders will also vote to ratify Grant Thornton LLP as the independent registered public accounting firm for the year ending December 31, 2025.
• The company forecasts granting approximately 30,000 shares per year over a three-year period, representing about 0.54% of shares outstanding as of May 16, 2025, excluding grants for new hospital openings.
• Net grants (grants less forfeitures) are estimated at approximately 24,000 shares over the next year, or 0.43% of shares outstanding as of May 16, 2025.
• As of May 12, 2025, there were 5,565,679 shares of common stock outstanding.
• The proposed 1,100,000 share increase represents a potential overall equity dilution of 19.76% and an annual equity dilution of 2.47% over the remaining eight years of the plan.
• After the proposed amendment, 1,106,620 shares would be authorized for future awards, representing 19.88% overall dilution or 2.48% annually.
• Outstanding equity instruments include 203,637 warrants (weighted average exercise price $97.68), 19,765 options (weighted average exercise price $331.40), and 135,030 unvested restricted stock units, totaling 358,432 securities.
• Historical annual burn rates were 0.57% in 2022, 0.09% in 2023, and 2.22% in 2024 (2.17% forfeiture-adjusted), with a three-year average of 1.05%.
• For 2025 to date, the burn rate is 1.08% based on 60,365 RSUs granted.
• The company recognized $36.0 million in stock-based compensation expense for the three months ended March 31, 2025, related to future obligations for Additional Merger Shares to former hospital owners, compared to $0 million for the same period in 2024.
• Minor typographical errors in proposal headings on pages 8, 23, 24, and 33 of the Proxy Statement have been corrected.

Sentiment

Score: 4

Explanation: While the company's burn rate is favorable compared to industry benchmarks and management expresses commitment to responsible equity management, the significant potential dilution from the proposed equity plan amendment and the substantial stock-based compensation expense related to past mergers present notable financial concerns. The growth strategy is positive but comes with considerable equity costs.

Positives

• The Board is committed to responsibly managing the growth of the equity compensation program to maximize stockholder value.
• The Compensation Committee, comprised solely of independent directors, ensures compensation programs align with stockholder interests and business goals.
• The company's three-year average burn rate of 1.05% and 2024 burn rate of 2.22% are significantly below the ISS United States Equity Compensation Plans Burn Rate Benchmark of 3.79% for Health Care Equipment & Services companies.
• The company engaged Mercer, a national compensation consulting firm, to assess executive compensation and ensure competitiveness.

Negatives

• The proposed amendment to the 2023 Equity Incentive Plan seeks to increase shares available by 1,100,000, representing a potential overall equity dilution of 19.76% and an annual dilution of 2.47% over the remaining 8 years of the plan, excluding a potential annual 5% evergreen increase.
• Recognized a substantial $36.0 million in stock-based compensation expense for the three months ended March 31, 2025, related to future obligations for Additional Merger Shares from past hospital mergers, a significant increase from $0 million in the prior year period.

Risks

• Potential significant dilution of existing stockholders due to the proposed increase in shares available under the 2023 Equity Incentive Plan and the potential annual 5% evergreen provision.
• Inability to predict the ultimate number of shares that will be issued under the 2023 Equity Incentive Plan over its remaining term, which could be substantially less or more than the requested reserve.
• Ongoing financial obligations related to Additional Merger Shares for former hospital owners, with the number of shares determined by operational results and stock price, leading to potentially volatile stock-based compensation expenses.

Future Outlook

The company expects to continue its growth strategy at similar levels, which will necessitate the issuance of incentive awards to anticipated new employees. The ultimate number of shares that will be issued under the 2023 Equity Incentive Plan over its remaining term cannot be predicted and may be substantially less than the 1,100,000 share reserve sought for approval.

Management Comments

• The Board recognizes that equity awards dilute existing stockholders and is therefore mindful to responsibly manage the growth of the equity compensation program.
• The Board is committed to effectively monitoring the equity compensation share reserve, including the amount of expected future award issuances, to ensure maximization of stockholder value by granting the appropriate number of equity awards necessary to attract, reward, and retain employees, directors, and consultants.
• The Compensation Committee ensures that the company's compensation programs are aligned with the interests of the company's stockholders and the company's business goals in order to attain the ultimate objective of increasing stockholder value.

Industry Context

The company's growth strategy involves opening new hospitals, aligning with expansion trends in the healthcare services sector. Its equity compensation practices are benchmarked against industry standards, specifically the ISS Burn Rate Benchmark for Health Care Equipment & Services companies in the Russell 3000, which is 3.79% per year.

Comparison to Industry Standards

• The company's three-year average burn rate of 1.05% is significantly below the ISS United States Equity Compensation Plans Burn Rate Benchmark of 3.79% per year for Health Care Equipment & Services companies in the Russell 3000.
• The 2024 burn rate of 2.22% (2.17% forfeiture-adjusted) is also well below the industry benchmark.

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders**: Face potential significant dilution from the proposed equity incentive plan amendment and the ongoing impact of stock-based compensation expense related to past mergers on financial results. Have the opportunity to vote on key corporate governance matters, including director elections and executive compensation.
• **Employees, Directors, and Consultants**: Will benefit from increased shares available for equity awards under the amended plan, enhancing the company's ability to attract, reward, and retain talent, particularly for new hospital openings.
• **Former Hospital Owners**: May receive additional merger consideration in the form of Additional Merger Shares based on the operational performance of their transferred hospitals, impacting their financial outcomes from the 2022 merger.

Next Steps

• Stockholders will attend and vote at the Annual Meeting on July 14, 2025.
• Votes will be cast on the re-election and election of directors, advisory executive compensation, the 2023 Equity Incentive Plan amendment, and auditor ratification.
• The company expects to continue its growth strategy by opening new hospitals, which will necessitate further incentive awards.

Key Dates

Recommendation

Keywords

Nutex Health, SEC filing, DEFA14A, proxy statement, equity incentive plan, stock options, restricted stock units, executive compensation, corporate governance, annual meeting, dilution, burn rate, stock-based compensation, hospital growth strategy, shareholder vote